title: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.
abstract: OBJECTIVE
  Binge eating disorder is associated with obesity. Topiramate is an antiepileptic agent associated with weight loss. The objective of this study was to evaluate topiramate in the treatment of binge eating disorder associated with obesity.
  
  
  METHODS
  For this 14-week, double-blind, flexible-dose (25-600 mg/day) topiramate trial, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index >/=30 kg/m(2)) were randomly assigned to receive topiramate (N=30) or placebo (N=31). The primary efficacy measure was binge frequency. The primary analysis of efficacy was a repeated-measures random regression with treatment-by-time as the effect measure.
  
  
  RESULTS
  Compared with placebo, topiramate was associated with a significantly greater rate of reduction in binge frequency, binge day frequency, body mass index, weight, and scores on the Clinical Global Impression severity scale and the Yale-Brown Obsessive Compulsive Scale (modified for binge eating). Topiramate was also associated with significantly greater reductions in binge frequency (topiramate: 94%, placebo: 46%) and binge day frequency (topiramate: 93%, placebo: 46%) and with a significantly higher level of response than placebo. The mean weight loss for topiramate-treated subjects who completed the study was 5.9 kg. Median topiramate dose was 212 mg/day (range=50-600). Nine patients (three receiving placebo, six given topiramate) discontinued because of adverse events. The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2).
  
  
  CONCLUSIONS
  Topiramate was efficacious and relatively well tolerated in the short-term treatment of binge eating disorder associated with obesity.
authors.affiliation: Division of Psychopharmacology Research, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267-0559, USA. susan.mcelroy@uc.edu
authors.forename: Susan L
authors.initials: SL
authors.lastname: McElroy
authors.forename: Lesley M
authors.initials: LM
authors.lastname: Arnold
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Shapira
authors.forename: Paul E
authors.initials: PE
authors.lastname: Keck
authors.forename: Norman R
authors.initials: NR
authors.lastname: Rosenthal
authors.forename: M Rezaul
authors.initials: MR
authors.lastname: Karim
authors.forename: Marc
authors.initials: M
authors.lastname: Kamin
authors.forename: James I
authors.initials: JI
authors.lastname: Hudson
mesh_terms: D000553:Ambulatory Care; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D002032:Bulimia / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000453:epidemiology; D010919:Placebos; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D010919:Placebos; D000077236:Topiramate; D005632:Fructose